Compare sp potential --- something I rarely do, bu

Compare sp potential --- something I rarely do, but LL is a rarity.

Nvidia:
2.5b shares
$1k per share

Sells chips.
Market competitors, who seems like weekly/monthly, announce advancements.

Projection is 5 year market dominance.

Cytodyn:
1b shares
.24 cents

Sells extension(s) of life.
Potentially 85% of Oncology.
Controls CCR5 axis via patents.

Projection is 18.5 years of dominance. (Just oncology)

Dr. J has said goal is non-dilutive funding.
Last letter said little to no cost to Cytodyn.

Selling 500m shares @ .25 = $125m.
Enough to trial a proof of MOA.

Still having 1b shares less than an Nvidia.

40k doses on hand & every increase above .25, makes for a very big difference. Not to mention Mitch won't need to raise the whole "$125m", @ once either.

Cytodyn is not financially backed up against a wall, as the share price is alluding to.

If secure a great colecterol trial funding agreement, it lays the foundation towards proving this Nvidia comparison.

& Nvidia didn't jump to a big board or sp heights overnight either.

Cytodyn could mimic their dominance, much quicker.

As posters pointed out ---- Cytodyn only needs 1 approval & LL can be subscribed for any disease.

Posters also point out --- Colecterol has the highest CCR5 of the cancers.

LL's odds of success, should be outstanding.

Shall see...... : )